Skip to main content

Table 1 Characteristics of patients with mucinous carcinoma and infiltrating ductal carcinoma

From: Pure mucinous carcinoma of the breast: clinicopathologic characteristics and long-term outcome among Taiwanese women

   MC (n = 93) IDC (n = 2,674) P
Age, years,    
  mean (SD) 49.77 (13.76) 50.68 (11.39) 0.529
  median 45.88 49.22  
  range 28, 85 15, 89  
Tumor size, cm,    0.185
  mean (SD) 3.06 (2.55) 2.69 (1.65)  
  median 2.50 2.30  
  range 0.20, 17.0 0.10, 15.0  
Tumor stage, n (%),    0.480
  T1 29 (34.12) 1123 (42.00)  
  T2 47 (55.29) 1297 (48.50)  
  T3 7 (8.24) 178 (6.66)  
  T4 2 (2.35) 76 (2.84)  
  unknown or other 8 0  
Grade, n (%),    <0.0001
  I 22 (66.67) 251 (14.13)  
  II 11 (33.33) 994 (55.97)  
  III 0 (0) 531 (29.90)  
  unknown or other 60 898  
Lymphovascular invasion, n (%),    <0.0001
  present 10 (15.38) 996 (47.41)  
  absent 55 (84.62) 1105 (52.59)  
  unknown or other 28 573  
ER status, n (%),    <0.0001
  positive 84 (90.32) 1715 (65.28)  
  negative 9 (9.68) 912 (34.72)  
  unknown or other 0 47  
PR status, n (%),    <0.0001
  positive 74 (79.57) 1555 (59.19)  
  negative 19 (20.43) 1072 (40.81)  
  unknown or other 0 47  
HER2/neu gene overexpression status, n (%),    0.023
  positive 8 (9.88) 467 (19.95)  
  negative 73 (90.12) 1874 (80.05)  
  unknown or other 12 333  
Lymph node status, n (%),    <0.0001
  positive 17 (19.77) 1144 (43.73)  
  negative 69 (80.23) 1472 (56.27)  
  not evaluated 7 58  
Primary treatment, n (%),    0.660
  mastectomy 59 (64.84) 1735 (67.27)  
  lumpectomy with RT 30 (32.97) 751 (29.12)  
  lumpectomy without RT 2 (2.20) 93 (3.61)  
  no surgery 2 95  
Systemic therapy, n (%),    <0.0001
  endocrine therapy alone 37 (44.05) 523 (21.02)  
  chemotherapy alone 6 (7.14) 603 (24.24)  
  endocrine therapy with chemotherapy 41 (48.81) 1362 (54.74)  
  none 8 186  
  unknown 1 0  
Follow up time, months    
  median 56 55  
  range 1.97-142 0.30-142  
10-year overall survival rate 0.9447 0.8611 0.042
  1. MC pure mucinous carcinoma, IDC infiltrating ductal carcinoma, ER estrogen receptor, PR progesterone receptor, RT radiotherapy.